bg
Effects of COVID-19 on Sopharma Trading
Sopharma Trading, being a wholesaler and retailer of pharmaceuticals, OTC products and cosmetics, is part of the companies at the forefront of the fight against COVID-19.
Weekly highlights: Sopharma Trading reported 10% sales growth in August 2019
Highlights from ELANA Weekly Wrap-Up for 30 September – 03 October 2019
Sopharma Trading’s consolidated revenues up 6.6% in H1 2019
Pharma wholesaler Sopharma Trading’s (SO5 BU) consolidated revenues accelerated 6.6% y/y to BGN 465.6m, net profit margin shrank on increased costs in H1’19, according to latest consolidated financials published by the Company.
Increase in all revenue streams for Sopharma Trading in H1 2018
Sopharma Trading boosted its standalone revenue by 8.2% y/y to BGN 352m and expanded bottom line by 13% y/y to BGN 8.1m in H1 2018, according to the Company’s interim financial statements. The top line expansion is a result of increase in all revenue streams of the Company.
New research report: Sopharma Trading – set for double expansion in 5 years
With 8.2% CAGR for the last 10 years and 7% average DY in the last 7 years, Sopharma Trading firmly leads the Bulgarian pharmaceuticals wholesale market. Following strong acquisition spree on the local and export markets in 2017, the Company is all set for a major expansion to nearly double in size in next 5… Read more
Sopharma Trading standalone top line expands by 10.4% in Q1 2018
Pharmaceuticals wholesaler Sopharma Trading expanded its standalone top line by 10.4% to BGN 181.7m in Q1’18 on higher sales in all segments, according to the Company’s financial statements for Q1’18.
Sopharma to vote BGN 39m profit to be distributed as dividend
Leading generic pharmaceuticals producer Sopharma proposed a BGN 0.11 dividend per share (DPS), the Company disclosed in a filing to the Trade Registry. This comes very short of ELANA Trading Research team BGN 0.12 DPS estimate.
New research report: Sopharma’s expansion mode is on
The biggest vertically integrated human health pharmaceutical group in Bulgaria Sopharma booked record performance in 2017 with the top line hitting BGN 1bn and best EBITDA ever on strong organic and M&A driven growth. Individual bottom line margins healthy above historical and peer averages at 20%+ as cost and group optimization kicked in.
Sopharma Trading plans further diversification and dynamic growth for the next three years
Sopharma Trading plans to diversify its business model and expand its market shares, the company’s CEO Dimitar Dimitrov announced in an interview in Bulgarian media Investor.bg.
Sopharma Trading receives green light to acquire PharmaStore
The Commission for Protection of Competition in Bulgaria has approved Sopharma Trading (SO5 BU)’s acquisition of the local PharmaStore harmacies chain. The Regulator’s decision comes after the company announced in March this year that it has reached the agreement for the acquisition of PharmaStore pharmacies operations (19 pharmacies in Bulgaria), with the intention of subsequently… Read more
